Track Repligen Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Repligen Corporation RGEN Open Repligen Corporation in new tab

104.20 USD
P/E
113.04
EPS
0.91
P/B
2.76
ROE
2.51
Beta
1.09
Target Price
178.74 USD
Repligen Corporation logo

Repligen Corporation

🧾 Earnings Recap – Q1 2026

The stock rose 6.4% following better-than-expected revenue growth, margin expansion, and an improved full-year adjusted EPS outlook supported by strong demand across segments and accelerated strategic initiatives.

  • Delivered 15% reported revenue growth (11% organic) with $194 million in Q1 sales, driven by broad-based strength across customer segments and geographies.
  • Adjusted operating margin expanded by 160 basis points, aided by disciplined cost management and the strategic sale of the low-margin Polymem business.
  • Maintained full-year organic growth guidance of 9% to 13%, while slightly lowering reported revenue guidance to reflect the Polymem divestiture, which improved margin expectations.
  • Growth led by Analytics (+50%+), Services (+30%+), and double-digit Consumables; strong capital equipment demand supported by easier comps and a healthy order funnel.
  • Advanced strategic priorities with the launch of a transformation office targeting at least one point of annualized margin improvement by end of 2027 and expanded partnerships in China, which delivered the best quarterly revenue in over two years.
📅
Loading chart...
Key Metrics
Earnings dateAug. 4, 2026
P/E113.04
EPS0.91
Book Value37.33
Price to Book2.76
Debt/Equity32.66
% Insiders5.233%
Growth
Revenue Growth0.15%
Earnings Growth0.48%
Estimates
Forward P/E40.30
Forward EPS2.55
Target Mean Price178.74

DCF Valuation

Tweak assumptions to recompute fair value for Repligen Corporation (RGEN)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Repligen Corporation Logo Repligen Corporation Analysis (RGEN)

United States Health Care Official Website Stock

Is Repligen Corporation a good investment? Repligen Corporation (RGEN) is currently trading at 104.20 USD. Market analysts have a consensus price target of 178.74 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 113.04. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Repligen Corporation is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is 2.55.

Investor FAQ

Does Repligen Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Repligen Corporation?

Repligen Corporation is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of 0.91.

Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Exchange Ticker
NMS (United States) RGEN
FRA (Germany) RGN.F

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion